A study assessing immune cell and gene expression profiles in peripheral blood mononuclear cells (PBMCs) before and after DAA treatment
Latest Information Update: 28 Jan 2021
Price :
$35 *
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 28 Jan 2021 New trial record